Nestlé Research - Clinical Research Unit - Clinical Innovation Lab
Lausanne, Canton of Vaud, 1000, Switzerland
NCT Number: NCT05266690
The primary research project objective is to investigate whether a maltodextrin with high degree of polymerization (Roquette Glucidex 2) and a dextran with comparable degree of polymerization (Pharmacosmos Dextran 10) have lower post-prandial glucose response than glucose syrup (Roquette Glucidex 40). To confer further robustness to the results, the post-prandial glucose response will be compared to a negative control represented by a resistant dextrin with a complex structure containing 70% non-digestible dietary fiber (Promitor 70), which is currently used for sugar replacement.
Additional key objective is to investigate the safety and gastrointestinal tolerability of the investigational products.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Not applicable
Lausanne, Canton of Vaud, 1000, Switzerland
The aim of the present research project is to generate comparative data on post-prandial glucose response (PPGR) of α-glucans varying systematically degree of polymerization and linkage type. These data are expected to contribute to the sugar replacement strategy in food industry.
An additional goal of the study is to demonstrate the feasibility of running a PPGR study remotely, i.e. with the participants carrying out most of the procedures at home.
Remote clinical trials (so called "virtual") have recently started to be implemented in pharmaceutical clinical research with the intent to reduce the burden on participants and investigational sites, narrow gaps with real life conditions, expand recruitment potential and maximize data collection. Nutritional research could be an even more suitable context for the remote approach because of the much lower safety risks for the participants.
However, with this innovative approach come new risks (at distance communication with the participants, complex data flows and logistics, lower degree of control on clinical trial execution) that can potentially affect the reliability of the study results and therefore require proper mitigation.
In the present study the following measures were put in place to reduce those risks:
The two products selected as positive and negative control for the present research project. Comparison of PPGR data generated in the present research project with existing data will allow evaluating the reliability of the remote approach compared to the traditional one.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Roquette Glucidex 2: Maltodextrins with high degree of polymerization
Pharmacosmos Dextran 10: Dextran with high degree of polymerization
Roquette Glucidex 40: Glucose syrup
Other names: Positive control
Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
Other names: Negative control
Time frame: From 0 (product intake) to 120 minutes
Incremental area under the concentration curve (iAUC 0 to 120 minutes) of post-prandial glucose in the interstitial subcutaneous fluid as measured by a continuous glucose monitoring (Flash Glucose Monitoring FGM) commercial device (Abbott Freestyle Libre), as absolute values or as relative value to the raise observed for a glucose syrup as positive control and a resistant dextrin containing a non-digestible fiber as negative control
Time frame: From 0 (product intake) to 120 minutes
Maximum concentration (Cmax) of post-prandial glucose in the interstitial subcutaneous fluid as measured by FGM device
Time frame: From 0 (product intake) to 120 minutes
Time of Cmax (Tmax) of post-prandial glucose in the interstitial subcutaneous fluid as measured by FGM device
Time frame: Through subject participation, up to 2 weeks
Incidence, type, severity and relation to the research product of possible adverse events experienced by the participants during the study
Time frame: Through subject participation, up to 2 weeks
Gastro-intestinal tolerability as assessed by visual analogue scale for the following symptoms: 1) Abdominal discomfort, 2) Decreased appetite, 3) Gastric reflux, 4) Nausea, 5) Diarrhea, 6) Headache
Time frame: Through subject participation, up to 2 weeks
Continuous heart rate measure (recorded by wearable activity tracker)
Time frame: Through subject participation, up to 2 weeks
Continuous physical activity measure (recorded by wearable activity tracker)
Société des Produits Nestlé (SPN)
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05453838
Postprandial Glucose Response
Utrecht, Netherlands
View Trial DetailsNCT04147273
Continous Glucose Measurement, Glycaemic Index
Düsseldorf, Germany
View Trial DetailsNCT07567443
Insulin Response, Lactose Digestion
View Trial Details